Drug intelligence / Profile preview

KSHB010

Development stage: Preclinical
Lead developer: Kashiv BioSciences

Overview

KSHB010 is a biosimilar candidate currently under development by Kashiv BioSciences. As of early 2025, the specific reference biologic and therapeutic target for KSHB010 have not been publicly disclosed by the company. According to Kashiv's pipeline, the program is in the preclinical stage, with development efforts focused on cell line and process development. Kashiv BioSciences is a vertically integrated biopharmaceutical company that develops and manufactures biosimilars, complex generics, and specialty biopharmaceutical products, leveraging its research and development and manufacturing facilities in the United States and India. The company's biosimilar portfolio also includes approved products such as Releuko (filgrastim-ayow) and Fylnetra (pegfilgrastim-pbbk).

Beyond the preview

Go deeper on KSHB010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KSHB010.

Explore the full profile